Displaying 551 - 560 of 640 results
-
Reducing opioid-related harm and building quality improvement capability in New Zealand: a national formative collaborativeThis poster 'Reducing opioid-related harm and building quality improvement capability in New Zealand: a national formative collaborative' was presented at the IHI's 28th annual national forum on quality improvement in health care.
-
Evaluation of the safe use of opioids national collaborativeThis report presents an evaluation of the Health Quality & Safety Commission-led safe use of opioids national collaborative.
-
ALERT 17: Alteplase or tenecteplase?An alert has been issued to highlight the need to clearly differentiate between stroke thrombolysis and myocardial infarction thrombolysis.
-
Applying for specify brand advice statusUse this application form to apply for a new or changed specify brand advice listing.
-
Specify brand advice guidance – updated May 2019Refreshed guidelines for the application of specify brand advice (SBA) for medicines within electronic systems.
-
Safe Medication Management newsletters - 2010Newsletters from the SMM programme for the year 2010
-
ALERT 4: Error-prone abbreviations, symbols and dose designations NOT TO USETo eliminate the risk associated with the use of error-prone abbreviations, symbols and dose designations when communicating any type of medicine-related information verbally, handwritten, pre-printed or electronically.
-
ALERT: MetoprololThis alert highlights recommended actions to reduce the risk in adults of 118.75mg oral metoprolol being administered when metoprolol 11.875mg is prescribed.
-
Safe use of opioids collaborative information for DHB hospitalsInformation document for DHBs about the breakthrough series collaborative on safe use of opioids in hospitals.
-
Safe use of opioids measurement: frequently asked questionsFrequently asked questions about measurement for the safe use of opioids.